Related Experiment Video
Updated: Dec 22, 2025
08:36
Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments
Published on: August 8, 2019
12.5K
Nonpharmacologic Management of Excessive Daytime Sleepiness.
1Department of Neurology, Center for Sleep Medicine, Weill Cornell Medical College of Cornell University, 425 East 61st Street, 5th Floor, New York, NY 10065, USA.
Sleep Medicine Clinics
|May 11, 2020
Summary
This review focuses on non-drug treatments for primary excessive daytime sleepiness. It explores optimal sleep needs and introduces a novel behavioral approach for managing daytime somnolence.
Area of Science:
- Sleep Medicine
- Behavioral Science
Background:
- Excessive daytime sleepiness (EDS) can significantly impair quality of life.
- Primary EDS is distinct from sleepiness secondary to other conditions.
- Understanding optimal sleep duration and individual sleep needs is crucial.
Purpose of the Study:
- To review non-pharmacologic treatments for primary EDS.
- To discuss the concept of sleep banking as a behavioral strategy.
- To propose and describe a novel behavioral intervention for daytime somnolence.
Main Methods:
- Literature review of non-pharmacologic interventions for EDS.
- Detailed discussion of optimal sleep parameters.
- Examination of sleep banking behavioral techniques.
- Introduction of a new behavioral treatment for daytime somnolence.
Main Results:
- Non-pharmacologic strategies are effective for primary EDS.
- Sleep banking shows potential as a management technique.
- A novel behavioral method for treating daytime somnolence is presented.
Conclusions:
- Non-drug interventions are vital for managing primary EDS.
- Further research into novel behavioral strategies is warranted.
- Addressing daytime sleepiness requires a comprehensive approach.
Related Concept Videos
01:19Management of Insomnia
437
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
437
01:13Insufficient Sleep and Sleep Deprivation
746
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
746
01:07Narcolepsy
380
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
380
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
412
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
412
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
282
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
282
01:27Insomnia
344
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
344